SG11201507259UA - P2x7 modulators - Google Patents
P2x7 modulatorsInfo
- Publication number
- SG11201507259UA SG11201507259UA SG11201507259UA SG11201507259UA SG11201507259UA SG 11201507259U A SG11201507259U A SG 11201507259UA SG 11201507259U A SG11201507259U A SG 11201507259UA SG 11201507259U A SG11201507259U A SG 11201507259UA SG 11201507259U A SG11201507259U A SG 11201507259UA
- Authority
- SG
- Singapore
- Prior art keywords
- modulators
- Prior art date
Links
- 101100135293 Mus musculus P2rx7 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361786260P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/027522 WO2014152604A1 (en) | 2013-03-14 | 2014-03-14 | P2x7 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201507259UA true SG11201507259UA (en) | 2015-10-29 |
Family
ID=50543353
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201700889PA SG10201700889PA (en) | 2013-03-14 | 2014-03-14 | P2x7 modulators |
SG11201507259UA SG11201507259UA (en) | 2013-03-14 | 2014-03-14 | P2x7 modulators |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201700889PA SG10201700889PA (en) | 2013-03-14 | 2014-03-14 | P2x7 modulators |
Country Status (33)
Country | Link |
---|---|
US (8) | US9066946B2 (hr) |
EP (3) | EP2970267B3 (hr) |
JP (1) | JP6293861B2 (hr) |
KR (4) | KR102516711B1 (hr) |
CN (2) | CN105209464B (hr) |
AR (2) | AR095530A1 (hr) |
AU (5) | AU2014239291B2 (hr) |
BR (1) | BR112015023142B1 (hr) |
CA (1) | CA2906085C (hr) |
CL (3) | CL2015002655A1 (hr) |
CY (1) | CY1119110T1 (hr) |
DK (2) | DK2970267T6 (hr) |
EA (1) | EA028816B1 (hr) |
ES (2) | ES2635318T7 (hr) |
HK (1) | HK1218541A1 (hr) |
HR (1) | HRP20171168T4 (hr) |
HU (1) | HUE032877T2 (hr) |
IL (1) | IL240880B (hr) |
JO (1) | JO3773B1 (hr) |
LT (1) | LT2970267T (hr) |
ME (1) | ME02802B (hr) |
MX (2) | MX364796B (hr) |
PH (1) | PH12015501930A1 (hr) |
PL (1) | PL2970267T6 (hr) |
PT (2) | PT2970267T (hr) |
RS (1) | RS56315B2 (hr) |
SG (2) | SG10201700889PA (hr) |
SI (1) | SI2970267T1 (hr) |
TW (2) | TWI599567B (hr) |
UA (1) | UA116467C2 (hr) |
UY (3) | UY39887A (hr) |
WO (1) | WO2014152604A1 (hr) |
ZA (1) | ZA201507627B (hr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9604982B2 (en) | 2013-03-14 | 2017-03-28 | Janssen Pharmaceutica Nv | P2X7 modulators |
JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
JO3773B1 (ar) | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | معدلات p2x7 |
GEP201706780B (en) | 2013-03-14 | 2017-11-27 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
GB201321748D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2015172196A1 (en) * | 2014-05-13 | 2015-11-19 | Monash University | Heterocyclic compounds and use of same |
JP6592510B2 (ja) | 2014-09-12 | 2019-10-16 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7調節因子 |
CN108047240B (zh) | 2014-09-12 | 2020-08-04 | 勃林格殷格翰国际有限公司 | 组织蛋白酶c的螺环化合物抑制剂 |
RU2683245C1 (ru) | 2015-04-24 | 2019-03-27 | Сионоги Энд Ко., Лтд. | 6-членные гетероциклические производные и содержащая их фармацевтическая композиция |
US10526325B2 (en) * | 2015-07-31 | 2020-01-07 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
RU2753524C2 (ru) | 2016-10-17 | 2021-08-17 | Сионоги Энд Ко., Лтд. | Бициклические азотсодержащие гетероциклические производные и включающие их фармацевтические композиции |
CA3045208A1 (en) * | 2016-12-02 | 2018-06-07 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis |
MY195013A (en) | 2017-03-13 | 2022-12-31 | Raqualia Pharma Inc | Tetrahydroquinoline derivatives as p2x7 receptor antagonists |
WO2019099509A1 (en) * | 2017-11-14 | 2019-05-23 | Second Genome, Inc. | Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder |
RS63312B1 (sr) * | 2018-01-30 | 2022-07-29 | Incyte Corp | Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on) |
CA3111309A1 (en) * | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
JOP20210058A1 (ar) * | 2018-09-28 | 2021-03-24 | Janssen Pharmaceutica Nv | مُعدلات ليباز أُحادِيُّ الجلِيسِريد |
CN109400605A (zh) * | 2018-11-27 | 2019-03-01 | 复旦大学附属中山医院 | 一种p2x7受体显像剂及其制备方法 |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
EP4038070A1 (en) * | 2019-09-30 | 2022-08-10 | Janssen Pharmaceutica NV | Radiolabelled mgl pet ligands |
JP7165647B2 (ja) | 2019-12-26 | 2022-11-04 | 信越化学工業株式会社 | 熱伝導性シリコーン樹脂組成物 |
WO2021145655A1 (ko) * | 2020-01-13 | 2021-07-22 | 압타바이오 주식회사 | 신규한 피라졸 유도체 |
CA3176946A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
CN115894452B (zh) * | 2021-08-18 | 2024-04-09 | 四川大学 | 一种p2x7受体抑制剂 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
EP0551432A1 (en) | 1990-10-02 | 1993-07-21 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo 4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
CA2493625A1 (en) | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20060135508A1 (en) | 2002-07-25 | 2006-06-22 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
FR2857363B1 (fr) | 2003-07-10 | 2007-09-07 | Aventis Pharma Sa | 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation |
AR045037A1 (es) * | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
JP2008510810A (ja) | 2004-08-23 | 2008-04-10 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−iv阻害剤としての縮合トリアゾール誘導体 |
US20080146612A1 (en) | 2005-01-27 | 2008-06-19 | Astrazeneca Ab | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2006110516A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
WO2009002423A2 (en) | 2007-06-21 | 2008-12-31 | Schering Corporation | Polycyclic guanine derivatives and use thereof |
NZ582056A (en) * | 2007-08-10 | 2012-08-31 | Lundbeck & Co As H | Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation |
FR2921342B1 (fr) | 2007-09-20 | 2010-03-12 | Airbus France | Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef |
EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
CA2722035C (en) | 2008-04-22 | 2016-10-11 | Janssen Pharmaceutica Nv | Quinoline or isoquinoline substituted p2x7 antagonists |
WO2010060854A1 (en) * | 2008-11-25 | 2010-06-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
WO2010066629A2 (en) | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
JP5654001B2 (ja) * | 2009-04-29 | 2015-01-14 | グラクソ グループ リミテッドGlaxo Group Limited | P2X7調節因子としての5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[4,3−a]ピラジン誘導体 |
GB0907515D0 (en) | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
US8871760B2 (en) | 2009-09-21 | 2014-10-28 | Roche Palo Alto Llc | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators |
EP2491031B1 (en) | 2009-10-23 | 2013-08-07 | Janssen Pharmaceutica N.V. | Fused heterocyclic compounds as orexin receptor modulators |
WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
EP2552920B1 (en) | 2010-04-02 | 2017-03-15 | Ogeda Sa | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
US20110252717A1 (en) | 2010-04-16 | 2011-10-20 | Graf Fernandez Rodrigo | Foldable structures for a construction |
WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
US9273947B2 (en) | 2012-02-07 | 2016-03-01 | Lg Innotek Co., Ltd. | Sensing magnet apparatus for motor |
JP5205547B1 (ja) | 2012-04-20 | 2013-06-05 | 株式会社ノイズ研究所 | 放射信号可視化装置 |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
IN2014MN02574A (hr) | 2012-05-22 | 2015-07-24 | Genentech Inc | |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
WO2014062732A1 (en) | 2012-10-15 | 2014-04-24 | Epizyme, Inc. | Substituted benzene compounds |
RS56283B1 (sr) | 2012-10-16 | 2017-12-29 | Janssen Pharmaceutica Nv | Metilen vezani hinolinil modulatori ror-gama-t |
KR20150074193A (ko) | 2012-11-01 | 2015-07-01 | 인사이트 코포레이션 | Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체 |
US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
BR112015014968A2 (pt) | 2012-12-21 | 2017-07-11 | Quanticel Pharmaceuticals Inc | inibidores de histona-desmetilase |
SG10201707095QA (en) | 2012-12-21 | 2017-09-28 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
CA2900012A1 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
NO335177B1 (no) | 2013-03-06 | 2014-10-13 | Cambi Technology As | Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse |
PE20151536A1 (es) | 2013-03-06 | 2015-10-28 | Janssen Pharmaceutica Nv | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina |
US9604982B2 (en) | 2013-03-14 | 2017-03-28 | Janssen Pharmaceutica Nv | P2X7 modulators |
WO2014159248A1 (en) | 2013-03-14 | 2014-10-02 | Newlink Genetics Corporation | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
GEP201706780B (en) | 2013-03-14 | 2017-11-27 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
JO3773B1 (ar) * | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | معدلات p2x7 |
KR102189529B1 (ko) | 2013-03-14 | 2020-12-11 | 큐라데브 파마 프라이버트 리미티드 | 키누레닌 경로의 억제제 |
AU2014230815B2 (en) | 2013-03-14 | 2016-12-08 | Glaxosmithkline Intellectual Property (No.2) Limited | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
US9840508B2 (en) | 2013-03-29 | 2017-12-12 | Oged Sa | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
EA201790600A1 (ru) | 2014-09-12 | 2017-07-31 | Янссен Фармацевтика Нв | Модулирующие p2x7 n-ацил-триазолопиразины |
JP6592510B2 (ja) | 2014-09-12 | 2019-10-16 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7調節因子 |
JOP20210058A1 (ar) | 2018-09-28 | 2021-03-24 | Janssen Pharmaceutica Nv | مُعدلات ليباز أُحادِيُّ الجلِيسِريد |
EP4038070A1 (en) | 2019-09-30 | 2022-08-10 | Janssen Pharmaceutica NV | Radiolabelled mgl pet ligands |
-
2014
- 2014-03-12 JO JOP/2014/0094A patent/JO3773B1/ar active
- 2014-03-12 TW TW103108579A patent/TWI599567B/zh active
- 2014-03-12 TW TW106128537A patent/TWI644671B/zh active
- 2014-03-14 AR ARP140101138A patent/AR095530A1/es active IP Right Grant
- 2014-03-14 SI SI201430279T patent/SI2970267T1/sl unknown
- 2014-03-14 UA UAA201510002A patent/UA116467C2/uk unknown
- 2014-03-14 US US14/212,669 patent/US9066946B2/en active Active
- 2014-03-14 RS RS20170758A patent/RS56315B2/sr unknown
- 2014-03-14 PL PL14718857T patent/PL2970267T6/pl unknown
- 2014-03-14 SG SG10201700889PA patent/SG10201700889PA/en unknown
- 2014-03-14 HU HUE14718857A patent/HUE032877T2/hu unknown
- 2014-03-14 KR KR1020227010005A patent/KR102516711B1/ko active IP Right Grant
- 2014-03-14 KR KR1020157029102A patent/KR102319857B1/ko active IP Right Grant
- 2014-03-14 CN CN201480027363.2A patent/CN105209464B/zh active Active
- 2014-03-14 PT PT147188577T patent/PT2970267T/pt unknown
- 2014-03-14 KR KR1020217034732A patent/KR102500076B1/ko active IP Right Grant
- 2014-03-14 MX MX2015012095A patent/MX364796B/es active IP Right Grant
- 2014-03-14 ES ES14718857T patent/ES2635318T7/es active Active
- 2014-03-14 PT PT17172541T patent/PT3239151T/pt unknown
- 2014-03-14 ES ES17172541T patent/ES2704024T3/es active Active
- 2014-03-14 SG SG11201507259UA patent/SG11201507259UA/en unknown
- 2014-03-14 UY UY0001039887A patent/UY39887A/es not_active Application Discontinuation
- 2014-03-14 UY UY0001039888A patent/UY39888A/es active IP Right Grant
- 2014-03-14 LT LTEP14718857.7T patent/LT2970267T/lt unknown
- 2014-03-14 US US14/775,432 patent/US10112937B2/en active Active
- 2014-03-14 ME MEP-2017-160A patent/ME02802B/me unknown
- 2014-03-14 EP EP14718857.7A patent/EP2970267B3/en active Active
- 2014-03-14 UY UY0001035469A patent/UY35469A/es active IP Right Grant
- 2014-03-14 CA CA2906085A patent/CA2906085C/en active Active
- 2014-03-14 JP JP2016502469A patent/JP6293861B2/ja active Active
- 2014-03-14 KR KR1020237010674A patent/KR20230049754A/ko not_active Application Discontinuation
- 2014-03-14 EP EP18204727.4A patent/EP3495365A1/en not_active Withdrawn
- 2014-03-14 BR BR112015023142-0A patent/BR112015023142B1/pt active IP Right Grant
- 2014-03-14 WO PCT/US2014/027522 patent/WO2014152604A1/en active Application Filing
- 2014-03-14 EA EA201591748A patent/EA028816B1/ru unknown
- 2014-03-14 DK DK14718857.7T patent/DK2970267T6/en active
- 2014-03-14 CN CN201811523767.7A patent/CN110003200B/zh active Active
- 2014-03-14 DK DK17172541.9T patent/DK3239151T3/en active
- 2014-03-14 AU AU2014239291A patent/AU2014239291B2/en active Active
- 2014-03-14 EP EP17172541.9A patent/EP3239151B1/en active Active
-
2015
- 2015-05-18 US US14/714,714 patent/US9464084B2/en active Active
- 2015-08-27 IL IL240880A patent/IL240880B/en active IP Right Grant
- 2015-09-02 PH PH12015501930A patent/PH12015501930A1/en unknown
- 2015-09-09 MX MX2022011795A patent/MX2022011795A/es unknown
- 2015-09-14 CL CL2015002655A patent/CL2015002655A1/es unknown
- 2015-10-13 ZA ZA2015/07627A patent/ZA201507627B/en unknown
-
2016
- 2016-06-07 HK HK16106529.9A patent/HK1218541A1/zh unknown
- 2016-09-07 US US15/258,320 patent/US10150765B2/en active Active
-
2017
- 2017-07-17 AU AU2017206153A patent/AU2017206153B2/en active Active
- 2017-07-25 CY CY20171100794T patent/CY1119110T1/el unknown
- 2017-07-31 HR HRP20171168TT patent/HRP20171168T4/hr unknown
- 2017-10-16 CL CL2017002609A patent/CL2017002609A1/es unknown
- 2017-10-16 CL CL2017002610A patent/CL2017002610A1/es unknown
-
2018
- 2018-11-20 US US16/196,140 patent/US10703749B2/en active Active
-
2019
- 2019-05-07 AU AU2019203186A patent/AU2019203186B2/en active Active
-
2020
- 2020-06-25 US US16/911,428 patent/US11225478B2/en active Active
-
2021
- 2021-07-23 AR ARP210102071A patent/AR123048A2/es unknown
- 2021-09-21 AU AU2021236451A patent/AU2021236451B2/en active Active
-
2022
- 2022-01-14 US US17/576,644 patent/US11820770B2/en active Active
-
2023
- 2023-10-18 US US18/381,554 patent/US20240116930A1/en active Pending
-
2024
- 2024-03-15 AU AU2024201709A patent/AU2024201709A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171168T4 (hr) | Modulatori p2x7 | |
HK1254111A1 (zh) | P2x7調節劑 | |
HK1232216A1 (zh) | 調製器 | |
HK1218651A1 (zh) | 調節劑 | |
HK1217489A1 (zh) | 調節劑 | |
GB201317802D0 (en) | SmartHaler patent application | |
HK1218542A1 (zh) | 調節劑 | |
IL242777A (en) | Building system elements | |
EP2975313A4 (en) | LIQUID RESTRAINT ELEMENT | |
GB201315731D0 (en) | Sealing member | |
PL2803518T3 (pl) | Uszczelniający element | |
GB201321601D0 (en) | Modulator | |
GB2518649B (en) | Sealing member | |
GB201312727D0 (en) | Modulators | |
GB201316031D0 (en) | Alignment member | |
GB201318298D0 (en) | Modulators | |
GB2517462B (en) | Sealing member | |
GB201317988D0 (en) | Modulators | |
GB201304473D0 (en) | Modulators | |
GB201310637D0 (en) | Sealing member | |
GB201317911D0 (en) | E e e | |
AU353325S (en) | Kettlebell | |
AP00812S1 (en) | Stumbelbloc | |
AU2013231V (en) | Bonsca7200 Scaevola aemula | |
AP2013000704S (en) | Gramoquat |